ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Ethnopharmacology
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1534967
Mechanism of Shenyuan Yiqi Huoxue Capsule alleviating coronary microvascular dysfunction: network analysis and experimental evidence
Provisionally accepted
- 1Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, China
- 2Hangzhou Lin'ping District Hospital of Traditional Chinese Medicine, Hangzhou, China
- 3Department of Traditional Chinese Medicine, Lhasa People's Hospital, Tibet Autonomous Region, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Shenyuan Yiqi Huoxue Capsule (SYYQ) has clinical evidence to improve coronary microvascular dysfunction (CMD) by tonifying qi and removing blood stasis, but the underlying mechanism remains unclear.Objective: This study aims to explore the mechanism by which SYYQ alleviates CMD through a combination of network analysis and both in vivo and in vitro experiments.Methods: First, network pharmacology was employed to predict the mechanism of SYYQ on CMD. Building upon the findings of network pharmacology, we conducted in vivo experiment to verify the improvement mechanism of SYYQ in CMD rats using echocardiography, histopathology, serum biochemistry, TUNEL staining, and transmission electron microscopy (TEM). In the context of cell experiments, we evaluated the characteristic changes in mice cardiac microvascular endothelial cells (MCMECs) and the molecular mechanism of SYYQ through cell transfection, TEM, western blotting, and qRT-PCR.Results: The results of network pharmacology suggest that SYYQ may enhance CMD through pathways related to apoptosis and vascular growth. Animal experiments demonstrated that SYYQ alleviated apoptosis, promoted microvascular opening, and reduced myocardial injury in CMD rats. Furthermore, cell experiments indicated that SYYQ mitigated apoptosis in hypoxic (Hyp) MCMECs, promoted the production of angiogenic factors. Furthermore, downregulation of miR-302-3p levels and activation of Hippo pathway were observed in Hyp MCMECs, which can be inhibited by SYYQ. When miR-302a-3p was overexpressed or the Hippo pathway was inhibited, the efficacy of SYYQ in promoting the production of angiogenic factors and inhibiting apoptosis in Hyp MCMECs was significantly enhanced. Additional studies revealed that miR-302a-3p negatively regulated LATS2.Conclusion: SYYQ improves CMD by promoting the production of angiogenic factors and inhibiting apoptosis via miR-302a-3p/Hippo.
Keywords: Coronary microvascular dysfunction, Apoptosis, Shenyuan Yiqi Huoxue capsule, Hippo pathway, miR-302a-3p, angiogenic factors
Received: 26 Nov 2024; Accepted: 16 Jul 2025.
Copyright: © 2025 Chen, JENNY, Liu, Li, Zong, Zhang, Li and Shi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Hongxu Liu, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, China
Xiang Li, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.